Full Press Release Details
Ted McKechnie Joins Lexaria Board of Directors
Kelowna, BC September 16, 2015 - Lexaria Corp.
(LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is happy to welcome
Mr. Ted McKechnie to its Board of Directors, effective immediately.
Ted is a senior entrepreneurial executive with extensive Board
and Senior Management Experience in the consumer goods industry with a proven
track record for achieving corporate financial and growth objectives. He is the
former President and COO of Maple Leaf Foods, which in 2014 had revenue of over
CDN $3.1 billion dollars.
He has held executive positions with Kraft, Frito Lay, General
Foods, PepsiCo, and Philip Morris Companies. He is the Founder, Chairman and CEO
of Canada s Technology For Food. Ted is an energetic leader experienced in
building teams in marketing, sales and supply chain management. Ted is the
recipient of the Philip Morris Chairman s Award for recognition of
extraordinary contributions having a significant and lasting impact on the
Ted will contribute to Lexaria s pursuit of excellence in hemp
oil fortified food manufacturing as well as assisting in opening retail
distribution channels.
I am delighted to welcome Ted to our Board of Directors, said
Chris Bunka, Chairman. Ted has vast experience in the food industry and his
knowledge and contacts within the industry throughout North America will be of
significant benefit to the Company. Mr. McKechnie is being awarded 100,000
restricted common shares, and options to purchase a further 100,000 restricted
common shares at US$0.19, valid for up to five years from date of issuance.
The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. About Lexaria
Lexaria is a food sciences company, with common shares quoted
in the USA with symbol LXRP and in Canada with symbol LXX. The company searches
for projects that could provide potential above-market returns.
To learn more about Lexaria Corp. visit
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations,
cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is
no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and
maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no
assurance that the medical marijuana, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing
capital is sufficient for the Company's needs or that it will not need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be
successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide
any increase in bioavailability to any individual person. There is no assurance that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will
protect against challenges from unknown third parties. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.